Industry Updates for the Psychedelics World | Page 24 of 35

Psychedelics News

Industry

22 Jul 2022

A Deeper Look at MindMed’s Corporate Update

MindMed has released its Corporate Overview....

By Jason Najum

Industry

20 Jul 2022

Learning From Wonderland: A Look at Psychedelics’ Top Event

Last year, Microdose provided a stomping ground for those interested and involved in the psychedelic medicine space, with over 1600 attendees, including sponsors and investors over two packed days with...

By Microdose

Industry

20 Jul 2022

Awakn’s Phase 3 Trial Approved for Government Funding

The UK’s National Institute for Health and Care Research (NIHR) has approved grant funding for 66% of the costs of Awakn’s Phase III clinical trial exploring the use of ketamine-assisted...

By Microdose NewsDesk

Industry

19 Jul 2022

Mydecine Files Patent Application For Short-Acting MDMA

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

13 Jul 2022

PharmaTher Granted Patent For Ketamine and Parkinson’s

Today we received another addition to PharmaTher's IP stockpile with a new patent for ketamine and the treatment of Parkinson’s and other motor disorders....

By Jason Najum

Finance, Industry

13 Jul 2022

Updated: Cathie Wood’s ARK Fund Buys More Atai Stock

Yesterday we received news of additional investment into Atai, with a purchase of 103,977 shares by Cathie Wood's ARK fund....

By Microdose NewsDesk

Industry

11 Jul 2022

In Psychedelic Investing, Long-Term Thinking Is Key

In the fast-growing field of psychedelic medicine, long-term investing is key....

By Microdose

Culture, Industry

6 Jul 2022

A Look at Psychedelics in the Media

Let’s take a look at recent psychedelic medicine headlines and see what the media has been saying as of late....

By Jason Najum

Industry

6 Jul 2022

ATAI Files For Potential $300M Capital Raise

Atai has filed a shelf prospectus for up tp $300 million in new capital...

By Jason Najum

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result